Patients with chronic neuropathic pain responded well to gabapentin monotherapy with residual pain after intravenous ceftriaxone treatment in a pilot study.
For treating hyperglycaemia in patients with type 2 diabetes, there is a growing number of approved antidiabetic agents available both as monotherapy and combination therapy.
